Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 17/20 | 0.60 |
| ▸ | CCNK | O75909 | 17/20 | 0.60 |
| ▸ | CDK9 | P50750 | 17/20 | 0.60 |
| ▸ | CDK12 | Q9NYV4 | 17/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 15/20 | 0.60 |
| ▸ | CDK2 | P24941 | 15/20 | 0.60 |
| ▸ | CDK7 | P50613 | 9/20 | 0.60 |
| ▸ | CCNH | P51946 | 9/20 | 0.60 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24588273 | 1.00 | CCNT1 (0.60) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24588775 | 0.96 | CCNT1 (0.62) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29699126 | 0.93 | CCNT1 (0.56) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL26627147 | 0.93 | CCNT1 (0.56) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL26627150 | 0.93 | CCNT1 (0.56) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24588278 | 0.91 | CCNT1 (0.62) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24588260 | 0.91 | CCNT1 (0.62) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29699095 | 0.90 | CCNT1 (0.60) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL26627130 | 0.90 | CCNT1 (0.60) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL26627127 | 0.90 | CCNT1 (0.60) | CCNT1CCNKCDK9CDK12CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124504-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-18 | — | — | US | disclosed |
| EP-4269403-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | GT Apeiron Therapeutics Limited (HK) | 2023-11-01 | — | — | EP | disclosed |
| CN-116745277-A | Aromatic heterocyclic compound, pharmaceutical composition and application thereof | 湃隆生物科技有限公司（香港） | 2023-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124504-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | CDK7, CDK17, CDK8 | CCNT1 47/4885CCNK 33/4885CDK9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.